Phase II Randomized Trial of Temozolomide and Concurrent Radiotherapy in Patients With Brain Metastases

替莫唑胺 医学 放射治疗 耐受性 恶心 化疗 呕吐 达卡巴嗪 临床研究阶段 内科学 外科 肿瘤科 不利影响
作者
Dosia Antonadou,M. Paraskevaidis,G. Sarris,Nikos Coliarakis,I. Economou,Pantelis Karageorgis,Nicolas Throuvalas
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:20 (17): 3644-3650 被引量:333
标识
DOI:10.1200/jco.2002.04.140
摘要

PURPOSE: To determine the efficacy, tolerability, and safety of concurrent temozolomide and radiotherapy in patients with previously untreated brain metastases. PATIENTS AND METHODS: Fifty-two patients with brain metastases from solid tumors were randomized to oral temozolomide (75 mg/m(2)/d) concurrent with 40-Gy fractionated conventional external-beam radiotherapy (2 Gy, 5 d/wk) for 4 weeks versus 40-Gy radiotherapy alone. The group receiving temozolomide and radiotherapy continued temozolomide therapy (200 mg/m(2)/d) for 5 days every 28 days for an additional six cycles. The primary end points were radiologic response and neurologic symptom evaluation. RESULTS: The objective response rate was significantly (P =.017) improved in patients receiving temozolomide and radiotherapy versus radiotherapy alone. Among 24 patients assessable for response in the temozolomide group, 23 (96%) of 24 responded, including nine (38%) patients with a complete response and 14 (58%) patients with a partial response. With radiotherapy alone, 14 (67%) of 21 assessable patients responded, including seven (33%) complete responses and seven (33%) partial responses. There was marked neurologic improvement in the group receiving temozolomide, and the proportion of patients requiring corticosteroids 2 months after treatment was lower in the temozolomide group compared with radiotherapy alone (67% v 91%, respectively). Daily temozolomide concurrent with radiotherapy was generally well tolerated; however, grade >or= 2 nausea (48% v 13%, P =.13) and vomiting (32% v 0%, P =.004) were significantly increased in the temozolomide group. Hematologic toxicity was predictable and reversible. CONCLUSION: Temozolomide is safe, and a significant improvement in response rate was observed when administered in combination with radiotherapy in patients with previously untreated brain metastases. A larger randomized trial is warranted to verify these results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
文献达人发布了新的文献求助10
刚刚
高贵的乐儿完成签到,获得积分10
刚刚
刚刚
619026854发布了新的文献求助10
1秒前
DongYue完成签到 ,获得积分10
1秒前
eloong发布了新的文献求助10
1秒前
Snoopy_Swan完成签到,获得积分10
2秒前
诊断性评估完成签到,获得积分10
2秒前
通通发布了新的文献求助30
2秒前
科目三的应助被小猪猪采纳,获得30
2秒前
2秒前
3秒前
Ava的应助被huaweili采纳,获得10
3秒前
4秒前
成功完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
lee发布了新的文献求助10
6秒前
Ee完成签到,获得积分10
6秒前
7秒前
微笑发布了新的文献求助10
7秒前
last_champion完成签到,获得积分10
7秒前
酷波er的应助被文献达人采纳,获得10
7秒前
7秒前
顺问冬安发布了新的文献求助10
7秒前
XFF发布了新的文献求助10
8秒前
8秒前
浅梦完成签到,获得积分10
8秒前
诚心的凡雁完成签到,获得积分10
8秒前
万能图书馆的应助被可妍昇采纳,获得10
9秒前
玉簪发布了新的文献求助10
9秒前
正直凌文完成签到,获得积分10
9秒前
9秒前
9秒前
9秒前
9秒前
10秒前
成功发布了新的文献求助10
10秒前
zhangmemng完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315